Lind Global discloses 557,143 position in ABVC, mostly warrants

Rhea-AI Filing Summary

ABVC BioPharma received an amended Schedule 13G filed by Lind Global Fund II LP, Lind Global Partners II LLC and Jeff Easton reporting beneficial ownership of 557,143 shares, equal to 3.2% of the outstanding common stock. The position is composed of 0 currently held common shares, 500,000 B Warrants and 57,143 shares issuable under convertible securities. Lind Global Partners II LLC and Mr. Easton report sole voting and dispositive power over the position.

The filing includes a certification that the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.

Positive

• Clear disclosure of beneficial ownership: 557,143 units and the 3.2% stake are explicitly reported.
• Detailed composition provided: filing specifies 500,000 B Warrants and 57,143 shares issuable under convertible securities.
• Sole voting and dispositive power disclosed: Lind Global Partners II LLC and Jeff Easton report control over the reported position.

Negative

• Position is under 5% (3.2%), limiting immediate influence over corporate control.
• Majority of exposure is non-equity (warrants and convertibles), so current voting power is limited despite economic exposure.

Insights

Financial Analyst

TL;DR Lind Global reports a 3.2% economic interest in ABVC, largely via warrants and convertible securities.

The filing discloses an aggregate beneficial position of 557,143 units (3.2%). That total comprises 500,000 B Warrants and 57,143 shares issuable upon conversion, with 0 currently held common shares. From a financial perspective, this structure provides economic exposure and potential future dilution but does not reflect immediate equity voting power beyond what is reported as sole voting/dispositive authority. The filing does not assert any intent to effect control.

Corporate Governance Expert

TL;DR Ownership is below 5% and the filers certify no intent to change control, limiting governance impact.

The reporting persons—Lind Global Fund II LP, its general partner Lind Global Partners II LLC, and Jeff Easton—identify sole voting and dispositive power over the reported position. Despite that declaration, the documented stake is 3.2% and the majority of the economic exposure is in derivative instruments (warrants and convertible securities). The submission includes a certification that the securities were not acquired to influence control, which is material to governance assessment.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 4)

ABVC BIOPHARMA, INC.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

00091F304

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 00091F304

1

Names of Reporting Persons

Lind Global Fund II LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 557,143.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 557,143.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

557,143.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.2 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: (1) The reporting person's ownership consists of (i) 0 shares of common stock, (ii) 500,000 warrants to purchase shares of common stock (the "B Warrants") and (iii) 57,143 shares of common stock issuable to the reporting person pursuant to convertible securities entered into between Lind Global Fund II and ABVC BioPharma, Inc. (the "Convertible Securities").

SCHEDULE 13G

CUSIP No. 00091F304

1

Names of Reporting Persons

Lind Global Partners II LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 557,143.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 557,143.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

557,143.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.2 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: (1) The reporting person's ownership consists of (i) 0 shares of common stock, (ii) 500,000 B Warrants and (iii) 57,143 shares of common stock issuable to the reporting person pursuant to the Convertible Securities.

SCHEDULE 13G

CUSIP No. 00091F304

1

Names of Reporting Persons

EASTON JEFF

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 557,143.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 557,143.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

557,143.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.2 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: (1) The reporting person's ownership consists of (i) 0 shares of common stock, (ii) 500,000 B Warrants and (iii) 57,143 shares of common stock issuable to the reporting person pursuant to the Convertible Securities.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ABVC BIOPHARMA, INC.
(b)	Address of issuer's principal executive offices: 44370 OLD WARM SPRINGS BLVD., FREMONT, California, 94538
Item 2.
(a)	Name of person filing: This statement is filed by the following entities and individuals (collectively, referred to as the "Reporting Persons"): o Lind Global Fund II LP, a Delaware limited partnership; o Lind Global Partners II LLC, a Delaware limited liability company; and o Jeff Easton, an individual and a citizen of the United States of America. Lind Global Partners II LLC, the general partner of Lind Global Fund II LP, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP. Jeff Easton, the managing member of Lind Global Partners II LLC, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.
(b)	Address or principal business office or, if none, residence: The address of the principal business office for each of the Reporting Persons is: 444 Madison Ave, Floor 41 New York, NY 10022
(c)	Citizenship: See Row 4 of cover page for each Reporting Person.
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 00091F304
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Row 9 of cover page for each Reporting Person.
(b)	Percent of class: See Row 11 of cover page for each Reporting Person.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Row 5 of cover page for each Reporting Person.
	(ii) Shared power to vote or to direct the vote: See Row 6 of cover page for each Reporting Person.
	(iii) Sole power to dispose or to direct the disposition of: See Row 7 of cover page for each Reporting Person.
	(iv) Shared power to dispose or to direct the disposition of: See Row 8 of cover page for each Reporting Person.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Lind Global Fund II LP

Signature:	By: Lind Global Partners II LLC, its General Partner, By: /s/ Jeff Easton
Name/Title:	Jeff Easton, Managing Member
Date:	08/13/2025

Lind Global Partners II LLC

Signature:	/s/ Jeff Easton
Name/Title:	Jeff Easton, Managing Member
Date:	08/13/2025

EASTON JEFF

Signature:	/s/ Jeff Easton
Name/Title:	Jeff Easton
Date:	08/13/2025

FAQ

How many shares does Lind Global beneficially own in ABVC (ABVC)?

The filing reports beneficial ownership of 557,143 units, representing 3.2% of the class.

What securities make up the reported ABVC position?

The position consists of 0 common shares held, 500,000 B Warrants, and 57,143 shares issuable pursuant to convertible securities.

Who filed the Schedule 13G/A for ABVC?

The reporting persons are Lind Global Fund II LP, Lind Global Partners II LLC (its general partner), and Jeff Easton.

Does the filing state any intent to influence ABVC's control?

The filing includes a certification that the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.

What voting or dispositive power is reported over the ABVC position?

The filers report sole voting power and sole dispositive power over the 557,143 units.